Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 16;7:81. doi: 10.1038/s41420-021-00456-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A Design and summary of the phosphoproteomic analysis of U251 cells treated ± DYRK1A inhibitors L41 and ALGERNON (ALG) for 72 h, and U251 shDYR cells treated ± DOX. B Venn diagram showing overlap among phosphopeptides significantly (ANOVA adj. P < 0.05 and Dunnett’s P < 0.05) reregulated by DYRK1A pharmacological inhibition (5,970 total) and genetic knockdown (1792 total). C A consensus sequence preference for DYRK1A. Motif enrichment analysis of 61 phosphopeptides regulated by both pharmacological and genetic inhibition that also possess an Arginine (R) in the –3 position, reveals a strong preference for Proline (P) in the +1 position. D Heatmap of phosphopeptide intensities (median log2 fold changes for treatment vs their respective controls) for phosphopeptides identified as potential DYRK1A substrates. E Heatmap of protein changes (median log2 fold changes of protein LFQ intensities for treatments vs their respective controls) for proteins on which phosphosites from panel D are found. F Kinase perturbation analysis with Kinase PA showing relative kinase activity in z-scores from DOX 48 h vs No DOX treatments (x-axis) and ALG (10 μM) vs untreated treatments (y-axis). G Kinase-substrate motif enrichment analysis for sites hyperphosphorylated in response to DYRK1A (DYR) inhibition. H Gene ontology over-representation analysis (Fischer’s exact test) of significantly hyperphosphorylated proteins in cells treated with ALG (10 μM, 72 h). I Annotation of CDK1 substrates (derived from PhosphoSitePlus) in the phosphoproteome of cells treated with ALG (10 μM, 72 h).